Hims & Hers (NYSE: HIMS) has skyrocketed 120% in just a month! Is it the next big disruptor in healthcare, or is it ...

Shares of Hims & Hers (NYSE: HIMS) stock are up nearly 500% in the past year, but is the stock in bubble territory, or is there still growth ahead? Travis Hoium tackles that question plus the ...

Fintel reports that on February 18, 2025, Morgan Stanley downgraded their outlook for Hims & Hers Health (NYSE:HIMS) from ...

It may be early, but some blazing investments have already delivered wealth-altering gains in this young year.

BTIG analyst David Larsen raised the firm’s price target on Hims & Hers (HIMS) to $85 from $35 and keeps a Buy rating on the shares. The ...

Is Hims & Hers a millionaire-maker in the making? Yes! Or, at least, it can be. There is a possible future where Hims & Hers ...

Direct-to-consumer telehealth company advertisement that aired during the Super Bowl failed to mention side effects of the drugs.

U.K.-based ad agency DAIVID said Pfizer had a strong, positive message with its ad and scored high with intense positive emotions. The commercial was also a top performer with spikes in positive ...

Pfizer clinches the top spot in the competitive 2025 Super Bowl ad race, promising groundbreaking visibility during the big ...

We recently published a list of 10 Firms Post Double-Digit Gains on Thursday. In this article, we are going to take a look at ...